Story

European MedTech and Life Sciences Show Stabilization, Deutsche Bank Says

ENTHMSVIIDZHZH-TWJAKOHI
Aug 26, 20262 min read
European MedTech and Life Sciences Show Stabilization, Deutsche Bank Says
Text size
Background

The European MedTech and Life Sciences sectors are showing signs of stabilization following a second-quarter earnings season that featured more beats than misses, according to a note from Deutsche Bank on Wednesday. However, the bank maintains a cautious outlook, citing that a sustained recovery will depend on a durable upward trend in earnings.

Q2 Earnings Signal a Shift

Analysts at the German bank observed that the Q2 reporting period was broadly positive, though some results were enhanced by non-operational items such as tariff refunds. A key development noted by the bank is a slowdown in negative earnings revisions.

While full-year consensus earnings revisions for 2027 remain negative across both sectors, Deutsche Bank reported that the magnitude of these downward cuts appears to be decreasing. This trend, combined with a stabilization in 2026 consensus estimates, has supported a slight re-rating for the sectors as investor positioning has increased.

Valuation and Headwinds

Despite the recent positive signs, valuations for European MedTech and Life Sciences companies remain at the low end of their historical ranges, according to the note. Deutsche Bank cautioned that a more significant re-rating would require a sustained upward trend in consensus earnings.

Sample IUX Markets – In-articleAd

The bank remains uncertain if this will materialize as the third quarter progresses. It highlighted the ongoing Middle Eastern conflict as a key risk that could fuel inflation, which would likely weigh on both sectors. Consequently, the bank's view remains cautious, particularly for MedTech.

Deutsche Bank's Top Picks

Following its analysis of the reporting season, Deutsche Bank identified three companies as its top picks:

  • Fresenius SE (FRE): The bank cited positive operational momentum in its Helios and Kabi segments and expects the company to manage the impact of German healthcare reform. The shares trade at 12 times the bank’s 2027 price-to-earnings estimate.
  • Lonza (LONN): The company is seen as well-positioned for strong performance into 2027, driven by robust end markets that are largely insulated from geopolitical headwinds. Its stock trades at 27 times the bank’s 2027 P/E estimate.
  • Ottobock (OBCK): Q2 results showed a clear acceleration from a softer Q1. Deutsche Bank expects strong growth and an improving margin profile to continue. The shares trade at 16 times its 2027 P/E estimate.

Read next

More on Stocks
Back to latest news

LATEST